Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.

Shin SB, Woo SU, Yim H.

Ther Adv Med Oncol. 2019 May 8;11:1758835919846375. doi: 10.1177/1758835919846375. eCollection 2019.

2.

Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.

Chae HS, Xu R, Won JY, Chin YW, Yim H.

Int J Mol Sci. 2019 May 16;20(10). pii: E2420. doi: 10.3390/ijms20102420. Review.

3.

Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21cip1.

Joo MS, Shin SB, Kim EJ, Koo JH, Yim H, Kim SG.

FASEB J. 2019 Mar 21:fj201802744R. doi: 10.1096/fj.201802744R. [Epub ahead of print]

PMID:
30897343
4.

7-O-Methylwogonin from Scutellaria baicalensis Disturbs Mitotic Progression by Inhibiting Plk1 Activity in Hep3B Cells.

Woo SU, Jang HR, Chin YW, Yim H.

Planta Med. 2019 Feb;85(3):217-224. doi: 10.1055/a-0731-0394. Epub 2018 Sep 10.

PMID:
30199903
5.

53BP1: A guardian for centrosomal integrity.

Kim H, Yim H.

Front Biosci (Landmark Ed). 2018 Jan 1;23:1-12.

PMID:
28930533
6.

Oligopeptide Competition Assay for Phosphorylation Site Determination.

Joo MS, Koo JH, Shin SB, Yim H, Kim SG.

J Vis Exp. 2017 May 18;(123). doi: 10.3791/55708.

7.

Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.

Shin SB, Woo SU, Lee YJ, Yim H.

Anticancer Res. 2017 Mar;37(3):1177-1183.

PMID:
28314279
8.

Roles of SALL2 in tumorigenesis.

Sung CK, Yim H.

Arch Pharm Res. 2017 Feb;40(2):146-151. doi: 10.1007/s12272-016-0874-x. Epub 2016 Dec 12. Review.

PMID:
27957650
9.

Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.

Shin SB, Woo SU, Chin YW, Jang YJ, Yim H.

J Cell Physiol. 2017 Oct;232(10):2818-2828. doi: 10.1002/jcp.25680. Epub 2017 Apr 10.

PMID:
27861885
10.

Antiinflammatory and analgesic effects of Eurycoma longifolia extracts.

Han YM, Woo SU, Choi MS, Park YN, Kim SH, Yim H, Yoo HH.

Arch Pharm Res. 2016 Mar;39(3):421-8. doi: 10.1007/s12272-016-0711-2. Epub 2016 Jan 30.

PMID:
26832325
11.

Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.

Shin SB, Woo SU, Yim H.

J Cell Physiol. 2015 Dec;230(12):3057-67. doi: 10.1002/jcp.25042.

PMID:
25975351
12.

The tumor suppressor protein p150(Sal2) in carcinogenesis.

Sung CK, Yim H.

Tumour Biol. 2015 Feb;36(2):489-94. doi: 10.1007/s13277-014-3019-1. Epub 2015 Jan 22. Review.

PMID:
25608837
13.

A mouse polyomavirus-encoded microRNA targets the cellular apoptosis pathway through Smad2 inhibition.

Sung CK, Yim H, Andrews E, Benjamin TL.

Virology. 2014 Nov;468-470:57-62. doi: 10.1016/j.virol.2014.07.052. Epub 2014 Aug 20.

14.

Predictive value of urinary and serum biomarkers in young children with febrile urinary tract infections.

Yim HE, Yim H, Bae ES, Woo SU, Yoo KH.

Pediatr Nephrol. 2014 Nov;29(11):2181-9. doi: 10.1007/s00467-014-2845-0. Epub 2014 Jun 13.

PMID:
24924751
15.

Plk1-targeted therapies in TP53- or RAS-mutated cancer.

Yim H, Erikson RL.

Mutat Res Rev Mutat Res. 2014 Mar 12. pii: S1383-5742(14)00019-2. doi: 10.1016/j.mrrev.2014.02.005. [Epub ahead of print]

PMID:
24630986
16.

ATM kinase promotes both caspase-8 and caspase-9 activation during TNF-α-induced apoptosis of HeLa cells.

Liu L, Yim H, Choi JH, Kim ST, Jin Y, Lee SK.

FEBS Lett. 2014 Mar 18;588(6):929-35. doi: 10.1016/j.febslet.2014.01.050. Epub 2014 Feb 11.

17.

Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.

Lee SJ, Hwang JW, Yim H, Yim HJ, Woo SU, Suh SJ, Hyun JJ, Jung SW, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.

J Gastroenterol Hepatol. 2014 Jun;29(6):1299-307. doi: 10.1111/jgh.12503.

PMID:
24372723
18.

Two nuclear export signals of Cdc6 are differentially associated with CDK-mediated phosphorylation residues for cytoplasmic translocation.

Hwang IS, Woo SU, Park JW, Lee SK, Yim H.

Biochim Biophys Acta. 2014 Feb;1843(2):223-33. doi: 10.1016/j.bbamcr.2013.10.024. Epub 2013 Nov 8.

19.

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.

Yim H.

Anticancer Drugs. 2013 Nov;24(10):999-1006. doi: 10.1097/CAD.0000000000000007. Review.

PMID:
23949254
20.

The accumulation of DNA repair defects is the molecular origin of carcinogenesis.

Cha HJ, Yim H.

Tumour Biol. 2013 Dec;34(6):3293-302. doi: 10.1007/s13277-013-1038-y. Epub 2013 Aug 2. Review.

PMID:
23907577

Supplemental Content

Loading ...
Support Center